drugset / Trial / NCT05995249
A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
Non-randomizedSequentialOpen-labelPrevention
Summary
The main aim of this study is to find out how the body of a healthy adult processes TAK-279 (pharmacokinetics) when substances that either hinder or help the human metabolism such as erythromycin, phenytoin and efavirenz are given along with TAK-279. Other aim is to learn about side effects and how well it is tolerated when TAK-279 is given alone and together with substances that impact human metabolism. The participants will need to stay at the clinic for up to 26 days.
Timeline
- Start
- 2023-08-11
- Primary completion
- 2023-12-18
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 600 mg | Oral |
| Subject | Erythromycin | Small molecule | 500 mg | Oral |
| Subject | Phenytoin | Unknown | 100 mg | Oral |
| Subject | Zasocitinib | Small molecule | 50 mg | Oral |
Indications
No indication recorded.